8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Cardiovascular121 citations

Terahertz Irradiation Improves Cognitive Impairments and Attenuates Alzheimer's Neuropathology in the APPSWE/PS1DE9 Mouse: A Novel Therapeutic Intervention for Alzheimer's Disease

Bioeffects Seen

Zhang J, Chen Y, Zhao Y, Wang P, Ding H, Liu C, Lyu J, Le W · 2024

Share:

Terahertz wave treatment demonstrated potential as a non-pharmacological therapeutic intervention for Alzheimer's disease by ameliorating cognitive deficits and key pathological hallmarks in a transgenic AD mouse model.

Plain English Summary

Summary written for general audiences

This study examined the effects of repeated low-frequency terahertz (THz) wave exposure on an Alzheimer's disease mouse model (APPSWE/PS1DE9). The researchers found that THz treatment significantly improved cognitive impairment and reduced AD neuropathology including amyloid-β deposition, tau hyperphosphorylation, mitochondrial dysfunction, neuroinflammation, and neuronal loss in the treated mice.

Why This Matters

This study represents early-stage preclinical research on an unconventional electromagnetic frequency range for neurodegeneration. While the findings are promising in an animal model, the mechanisms by which THz waves produce these effects remain unclear, and translation to human therapeutic applications would require extensive further investigation.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Zhang J, Chen Y, Zhao Y, Wang P, Ding H, Liu C, Lyu J, Le W (2024). Terahertz Irradiation Improves Cognitive Impairments and Attenuates Alzheimer's Neuropathology in the APPSWE/PS1DE9 Mouse: A Novel Therapeutic Intervention for Alzheimer's Disease.
Show BibTeX
@article{zhang_j_chen_y_zhao_y_wang_p_ding_h_liu_c_lyu_j_le_w_ce3582,
  author = {Zhang J and Chen Y and Zhao Y and Wang P and Ding H and Liu C and Lyu J and Le W},
  title = {Terahertz Irradiation Improves Cognitive Impairments and Attenuates Alzheimer's Neuropathology in the APPSWE/PS1DE9 Mouse: A Novel Therapeutic Intervention for Alzheimer's Disease},
  year = {2024},
  doi = {10.1016/s0140-6736(24)01028-6},
  
}
DOI: 10.1016/s0140-6736(24)01028-6PubMed: 37971654

Quick Questions About This Study

Yes, the study found no difference in treatment effectiveness based on diabetes status. Both diabetic and non-diabetic patients showed similar cardiovascular benefits from targeting blood pressure below 120 mmHg versus below 140 mmHg.
The study included 3,022 participants with previous stroke history out of 11,255 total participants. These stroke patients showed the same cardiovascular benefits from intensive blood pressure treatment as other high-risk patients.
During follow-up, the intensive treatment group averaged 119.1 mmHg systolic pressure while the standard treatment group averaged 134.8 mmHg. This 15.7 mmHg difference led to a 12% reduction in major cardiovascular events.
Syncope (fainting) occurred more frequently in the intensive group (0.4% vs 0.1%), but other serious adverse events like hypotension, falls, or kidney injury showed no significant differences between treatment approaches.
Participants were followed for a median of 3.4 years after enrollment between September 2019 and July 2020. This extended follow-up period was necessary to detect meaningful differences in cardiovascular outcomes between treatment strategies.